SK Biopharmaceuticals hoping for a 1-trillion-won silver bullet
SK Biopharmaceuticals, a wholly-owned subsidiary of SK Holdings, is hoping for a near 1-trillion-won ($823 million) initial public offering (IPO) bonanza that will be the company's silver bullet, allowing it to secure a beachhead in the cutthroat...